Project Grant HT9425261E276
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a Project Grant of $4.397 million under the Military Medical Research and Development program (CFDA 12.420) on November 1, 2025, with an ultimate completion date of October 31, 2028. This grant funds research on extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia. The project addresses critical medical challenges affecting Service Members by...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $575,968 Project Grant effective September 30, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct an efficacy and feasibility trial of a portable near-infrared hematoma imager for detection of intracranial hemorrhage in acute care settings. The two-year research initiative, concluding September 29, 2027, will be performed in Tacoma, Washington, and focuses...
- Federal Project Grant Award Summary The Geneva Foundation received a $4.82 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded July 15, 2025, with a completion date of July 14, 2028. The award funds the development of a patient-matched segmental defect implant system with mechanobiologic activation and antimicrobial coating designed to treat severe fractures. This research initiative represents an...
- Federal Grant Award Summary The Geneva Foundation received a $1,009,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, for a three-year performance period ending July 31, 2028. The award supports genomic and functional characterization of chemoresistance in small cell lung cancer, a research initiative conducted at the foundation's facility in Tacoma, Washington. This project contributes to...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $747,394 Project Grant on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on antagonism-enforced braking system Chimeric Antigen Receptor T-cell (CAR T-cell) therapies for the treatment of TP53-mutant breast cancer. The three-year project, scheduled for completion on March 31, 2029, will be conducted at The Geneva Foundation's facility in...
- Federal Project Grant Award Summary The Geneva Foundation received a $909,510 Project Grant awarded May 1, 2025, by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support precision therapy research for the eradication of brain metastatic breast cancer. The three-year award, with an ultimate completion date of April 30, 2028, will be performed at the foundation's Tacoma, Washington facility. This research initiative aligns with the...
- Federal Project Grant Award Summary The Geneva Foundation received a $487,800 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025 through September 30, 2027. The award funds research to define the cellular origins and molecular vulnerabilities of Notch-driven lymphomas. This research initiative contributes to the Defense Health Agency's broader mission of transforming healthcare for service members...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $488,276 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the development of antagonism-enforced braking system chimeric antigen receptor T-cell (CAR T-cell) therapeutics for the treatment of TP53-mutant breast cancer. The three-year project, initiated April 1, 2026 and concluding March 31, 2029, represents DHA's investment in advancing cancer immunotherapy...
- Federal Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $547,103 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 30, 2026, with a completion date of September 29, 2028. The project focuses on developing CD79A-directed nanobody therapeutics for drug-resistant B-cell lymphomas, representing translational oncology research aligned with the program's mission to advance medical solutions for Service Member...
- Federal Project Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $999,766 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The award supports research to accelerate personalized T-cell receptor (TCR) immunotherapy for microsatellite-stable colorectal cancer through development of a multimodal prediction model. This research initiative addresses a significant clinical...
The Defense Health Agency (DHA) awarded The Geneva Foundation a $1.25 million Project Grant on September 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to establish a burn registry during large-scale combat operations. The three-year project, scheduled for completion by September 14, 2029, will be performed in Tacoma, Washington. This initiative supports the DHA's mission to advance biomedical research addressing Service Member health and battlefield medicine by developing a centralized registry to capture clinical data and outcomes from burn casualties sustained during large-scale military operations, enabling evidence-based improvements to burn injury management protocols and clinical care standards for military personnel. The Geneva Foundation, a 501(c)(3) nonprofit biomedical research organization, will leverage its extensive experience in military medical research and combat casualty care to design, implement, and maintain the registry infrastructure. The foundation's recent work in related areas—including prior DHA grants for extracorporeal immunomodulation to reduce inflammation after severe burns and septicemia ($4.4 million, November 2025) and blood transfusion optimization ($2.3 million)—demonstrates relevant technical capability. Outcomes from this registry are expected to generate clinical insights and data that inform future treatment protocols and contribute to the broader portfolio of DHA-supported research on combat trauma and mass casualty management.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 6/8/26 |